Our team went through many data sources and prepared COVID-19 response of the life sciences industry deck. We will keep sharing this deck monthly as new companies developing diagnostics, treatment and vaccine are joined to fight COVID-19.
To download the deck, here is the link.
Topics covered in the deck:
The pandemic spreads incredibly quickly between people. More than 6m people infected in appr. 5 months
Overview
•Origin: Possibly in wet animal market in Wuhan, China
•Disease: Coronavirus disease 2019 (COVID-19)
•Cause: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
•Strain: Same virus as SARS-CoV-1, which affected 8,000 people in 2002-03
•DNA Study (Feb-2020): 96% DNA match between bat coronavirus and human suggests link to humans is not direct but through intermediate host
•Target: Upper respiratory tract and can spread to lungs
Transmission & Mechanism
•Enters through nose, mouth, or eyes
•Attaches to cells in the respiratory tract producing a protein called ACE2
•It fuses with the cell and releases the RNA
•The hijacked infected cell will produce proteins based on the “instructions” from the virus’ RNA
•Each infected cell can release millions of copies of the virus before dying
Characteristics
•Virus appears highly transmissible - Average patient infects 1.6 to 2.4 other people
•Affects older patients and fatality rate in the 70s is 3-4 times larger than the average
Men are twice more likely to get infected than women
Global stock markets spooked by surge in cases
Leading companies have joined forces to strengthen the industry’s response against the COVID-19 pandemic
Diagnostics, Treatment and Vaccine
Slowdown of Economic Growth
Demand Disruption
Operations Disruption
Impact on Regulatory Function
Increase in Costs
Product Launch Delays
Virology Science
Clinical Trial Delays
Secure Core Operations
Prioritize Clinical Trials
Revise Operating Model
Reduce Dependencies/Risks
Re-evaluate Strategy Plans
Revise Operating Model
Boost Commercial Activities
Acquisitions & Divestments
Enterprise Risk Management
Resume R&D Activities
Ensure Business Continuity
Re-evaluate Strategy Plans
Revise Operating Model
Boost Commercial Activities
Acquisitions & Divestments
Enterprise Risk Management
Operational Improvement
Ensure Business Continuity
COVID-19 Response of the Life Sciences Industry Leading companies have joined forces to strengthen the industry’s response against the COVID-19 pandemic
1. Diagnostics
Diagnostic Testing The most pressing and immediate need in the battle against COVID-19
2. Treatments
Treatment Development Pharma companies and biotechs are racing to develop an effective treatment for the COVID-19
3. Vaccine
Vaccine Life Sciences companies are ratcheting up their efforts with accelerated schedules for creating new vaccines
Basics about SARS-CoV-2 & COVID-19
Anatomy of the Virus: SARS-CoV-2
Cellular Pathogenesis of the Virus: SARS-CoV-2
Covid-19 Disease Progression and Multi-Organ Injuries
Three Clinical Phases of Covid-19 Infection and Disease Progression
Almost 90% of Covid-19 Hospital Admissions involve Comorbidities
Potential Therapeutic Targets for SARS-CoV-2
Daily Death Tolls by Country
Daily Deaths per Day by Country and Region
Mapping the Covid-19 outbreak
Covid-19 situation in Europe & US
Many Major Countries are still seeing rapid case growth.
Comparison of Tests, Cases and Deaths
Death rates 2020 vs Historical Averages by Country
Death rates 2020 vs Historical Averages by Urbans
Excess Mortality Since Region/Country’s First 50 Covid-19 Deaths
Total COVID-19 tests per 1,000 vs. GDP per capita
Comparison of Tests vs Cases
Comparison of Median Age and Death Rate
The Countries with Critical Care Beds vs Active Cases
Populations Impact on Countries’ Death Tolls
Lockdown Timing Impact on Countries’ Death Tolls
Covid-19 Major Events in Global
Timeline of US Government Responses to Covid-19
Timeline of EU5 Government Responses to Covid-19
Entering lockdown and lockdown easing, by country
The Public-Health Tools and Approaches
Places Restricting Travel Because of the Outbreak
COVID-19 reported infections in EU5 – by age